On June 26, Finnegan client Cumberland Pharmaceuticals filed suit against Sagent Pharmaceuticals Inc. and Sagent Agila LLC, in response to the Sagent companies’ ANDA application seeking approval to market a generic version of Cumberland’s Acetadote®. Cumberland holds U.S. Patent No. 8,148,356, which covers the next generation formula of its Acetadote® product through 2025. Cumberland is represented by Finnegan in this matter.
